Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms: Inhibitors of DNA methylation and histone deacetylation: promising tools against cancer
8 Angebote vergleichen
| Preise | 2013 | 2014 | 2015 | 2019 |
|---|---|---|---|---|
| Schnitt | € 48,04 | € 63,07 | € 63,05 | € 51,27 |
| Nachfrage |
1
Symbolbild
Epigenetic Therapy of Mhc Class I Tumors and Myeloid Neoplasms
DE PB NWISBN: 9783659412127 bzw. 3659412120, in Deutsch, LAP LAMBERT Academic Publishing, Taschenbuch, neu.
Von Händler/Antiquariat, BuySomeBooks [52360437], Las Vegas, NV, U.S.A.
Paperback. 92 pages. Dimensions: 8.7in. x 5.9in. x 0.2in.Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e. g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer. This item ships from multiple locations. Your book may arrive from Roseburg,OR, La Vergne,TN.
Paperback. 92 pages. Dimensions: 8.7in. x 5.9in. x 0.2in.Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e. g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer. This item ships from multiple locations. Your book may arrive from Roseburg,OR, La Vergne,TN.
2
Symbolbild
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms (2013)
DE PB NW RPISBN: 9783659412127 bzw. 3659412120, in Deutsch, Lap Lambert Academic Publishing Jun 2013, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, AHA-BUCH GmbH [51283250], Einbeck, Germany.
This item is printed on demand - Print on Demand Titel. Neuware - Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer. 92 pp. Englisch.
This item is printed on demand - Print on Demand Titel. Neuware - Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer. 92 pp. Englisch.
3
Symbolbild
Epigenetic Therapy of Mhc Class I Tumors and Myeloid Neoplasms (Paperback) (2013)
DE PB NW RPISBN: 9783659412127 bzw. 3659412120, in Deutsch, LAP Lambert Academic Publishing, United States, Taschenbuch, neu, Nachdruck.
Lieferung aus: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, The Book Depository EURO [60485773], Slough, United Kingdom.
Language: English Brand New Book ***** Print on Demand *****.Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer.
Von Händler/Antiquariat, The Book Depository EURO [60485773], Slough, United Kingdom.
Language: English Brand New Book ***** Print on Demand *****.Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer.
4
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms - Inhibitors of DNA methylation and histone deacetylation: promising tools against cancer
~EN PB NWISBN: 9783659412127 bzw. 3659412120, vermutlich in Englisch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms: Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer. Englisch, Taschenbuch.
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms: Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer. Englisch, Taschenbuch.
5
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms
~EN NW ABISBN: 9783659412127 bzw. 3659412120, vermutlich in Englisch, neu, Hörbuch.
Lieferung aus: Niederlande, Lieferzeit: 5 Tage, zzgl. Versandkosten.
Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer.
Epigenetic agents such as DNA methyltransferase inhibitors and inhibitors of histone deacetylase are currently used in clinical studies to reverse altered histone modifications and aberrant DNA methylation which can lead to tumor growth. Because epigenetic modifications are functionally equivalent to genetic changes and some have been linked to tumorigenic events, researchers have attempted to identify epigenetic mechanisms that may lead to disease such as cancer. Recent data has shown that the use of these agents positively influence the induction of down-modulated immunoactive(e.g. MHC class I or II), co-stimulatory and adhesive molecules on tumor cells, cytokine production and the expression of tumor-rejecting antigens. Therefore, the anti-tumor therapeutic potential of these agents is promising and are welcomed additions to the medicinal arsenal currently used in the fight against cancer.
6
Symbolbild
Epigenetic Therapy of Mhc Class I Tumors and Myeloid Neoplasms (2013)
DE PB NW RPISBN: 9783659412127 bzw. 3659412120, in Deutsch, LAP Lambert Academic Publishing, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, English-Book-Service - A Fine Choice [1048135], Waldshut-Tiengen, Germany.
This item is printed on demand for shipment within 3 working days.
This item is printed on demand for shipment within 3 working days.
7
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms
~EN NWISBN: 3659412120 bzw. 9783659412127, vermutlich in Englisch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
8
Epigenetic Therapy of MHC class I Tumors and Myeloid Neoplasms
~EN PB NWISBN: 9783659412127 bzw. 3659412120, vermutlich in Englisch, Taschenbuch, neu.
Lieferung aus: Deutschland, Next Day, Versandkostenfrei.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…